- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02894853
Lung Cancer Early Molecular Assessment Trial (LEMA)
September 13, 2017 updated by: The Netherlands Cancer Institute
The investigators hypothesize that an early molecular profiling, that includes both tissue and blood-bases analysis, for all NSCLC patients, including stage I-III, will increase diagnostic efficiency.
When molecular profiles are available at an earlier stage of disease, more patients will benefit from personalized therapy once needed.
This will result in both a better quality of life and outcome.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
In this prospective multicentre trial tumours of all patients presenting with NSCLC will be profiled upfront, irrespective of disease stage and pathology using both tissue and blood-based genetic testing.
A minimal molecular profiling is depicted but other targets will be included in due time.
The study is divided in two parts.
In the first part participating centres will have a run-in period of half a year in which molecular profiling is performed as is currently standard of care.
This period will be used to measure the impact of increased awareness on the diagnostic process.
During the second part of the study a comprehensive upfront profiling according to local standards will take place for all NSCLC patients.
Liquid (blood) biopsies will be included in order to increase the diagnostic yield for those patients where tissue biopsies are not adequate.
Patients will be treated according to standard of care, or included in clinical studies where appropriate.
Re-biopsies (both tissue and liquid) will be advocated at the time of establishing disease progression/disseminated disease, and personalized therapy will be initiated according to the existing data from the molecular profiling.
Study Type
Observational
Enrollment (Anticipated)
1297
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michel van den Heuvel, MD
- Phone Number: 9111 0031-20-512
- Email: m.vd.heuvel@nki.nl
Study Contact Backup
- Name: Robert Schouten, MSc
- Phone Number: 9111 0031-20-512
- Email: r.schouten@nki.nl
Study Locations
-
-
North-Holland
-
Amsterdam, North-Holland, Netherlands, 1066CX
- Recruiting
- Antoni van Leeuwenhoek
-
Contact:
- Michael van den Heuvel, MD
- Phone Number: 9111 +31-20-512
- Email: m.vd.heuvel@nki.nl
-
Contact:
- Robert Schouten, MD
- Phone Number: 9111 +31-20-512
- Email: r.schouten@nki.nl
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
All patients presenting with NSCLC will be profiled upfront, irrespective of disease stage and pathology using both tissue and blood-based genetic testing
Description
Inclusion Criteria:
- Suspicion of lung carcinoma or established NSCLC but awaiting start of definitive treatment
- Written informed consent to undergo diagnostic procedure and molecular analysis of the disease.
Exclusion Criteria:
- Not motivated to receive any treatment at any point in time. Patients who consider undergoing treatment in the future are eligible.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients with EGFR mutation or ALK translocation using the combined tumour tissue and liquid biopsy analysis
Time Frame: 3 years
|
Patients with EGFR mutation or ALK translocation using the combined tumour tissue and liquid biopsy analysis
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Include the test performance of both techniques in different stage of disease
Time Frame: 3 years
|
Test performance of both techniques in different stage of disease
|
3 years
|
The percentage of patients with a predefined actionable genetic alteration
Time Frame: 3 years
|
Patients with a predefined actionable genetic alteration
|
3 years
|
The costs
Time Frame: 3 years
|
The costs
|
3 years
|
The influence of the liquid biopsies on the diagnostic yield of tissue molecular and pathological analysis.
Time Frame: 3 years
|
Liquid biopsies on the diagnostic yield of tissue molecular
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michel van den Heuvel, MD, Antoni van Leeuwenhoek
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2016
Primary Completion (Anticipated)
June 1, 2019
Study Completion (Anticipated)
December 1, 2019
Study Registration Dates
First Submitted
September 5, 2016
First Submitted That Met QC Criteria
September 8, 2016
First Posted (Estimate)
September 9, 2016
Study Record Updates
Last Update Posted (Actual)
September 14, 2017
Last Update Submitted That Met QC Criteria
September 13, 2017
Last Verified
September 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- M15LEM
- NL54778.031.15 (Other Identifier: METC-AVL)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Liquid (blood) biopsies and tumor biopsy (optional)
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingHereditary Diffuse Gastric CancerFrance
-
Institut CurieCompletedCervical CancerFrance, Germany, Netherlands, Romania, Serbia
-
Institut CurieRecruitingCervical Cancer | Head and Neck Cancer | Ovarian Cancer | Triple-Negative Breast CancerFrance
-
SOLTI Breast Cancer Research GroupMerck Sharp & Dohme LLC; Pfizer; AstraZeneca; Astellas Pharma Inc; Advanced Accelerator... and other collaboratorsRecruiting
-
University Hospital, MontpellierNot yet recruitingPancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Minimal Residual Disease | Liquid Biopsy | ctDNA
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEpithelial Ovarian Cancer | OrganoidsItaly
-
University Health Network, TorontoCanadian Cancer Society (CCS); Brain CanadaRecruitingBrain Neoplasms | Liquid BiopsyCanada
-
Centre Oscar LambretUniversity Hospital, LilleTerminated